Published in Health Serv Res on October 29, 2009
Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11. Health Aff (Millwood) (2014) 0.91
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer (2013) 0.82
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res (2012) 0.79
Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Adv Ther (2016) 0.75
Physician Agency and Patient Survival. J Econ Behav Organ (2016) 0.75
Is there empirical evidence for decreasing returns to scale in a health capital model? Health Econ (2012) 0.75
Recent trends in the probability of high out-of-pocket medical expenses in the United States. SAGE Open Med (2016) 0.75
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. J Oncol Pract (2015) 0.75
Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD. Eur J Health Econ (2013) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 6.80
Trends in Medicare payments in the last year of life. N Engl J Med (1993) 5.27
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med (2003) 3.88
Benefit design and specialty drug use. Health Aff (Millwood) (2006) 3.44
Value-based insurance design. Health Aff (Millwood) (2007) 3.27
An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health (2009) 2.60
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Cost-effectiveness as a price control. Health Aff (Millwood) (2007) 2.11
Do oncologists believe new cancer drugs offer good value? Oncologist (2006) 1.80
Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) (2000) 1.70
The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care (1994) 1.39
Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ (2005) 1.35
An inquiry into the different perspectives that can be used when eliciting preferences in health. Health Econ (2003) 1.31
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer (2007) 1.26
Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat (2004) 1.17
Tier 4 drugs and the fraying of the social compact. N Engl J Med (2008) 1.16
Costs of severely ill members and specialty medication use in a commercially insured population. Health Aff (Millwood) (2008) 1.01
Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat (2007) 0.93
Patterns of care for men with prostate cancer after failure of primary treatment. Cancer (2006) 0.79
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Prespecified falsification end points: can they validate true observational associations? JAMA (2013) 3.11
Trends in the earnings of male and female health care professionals in the United States, 1987 to 2010. JAMA Intern Med (2013) 2.97
Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. Ann Intern Med (2010) 2.93
Why physicians work when sick. Arch Intern Med (2012) 2.65
The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. Health Aff (Millwood) (2011) 2.64
Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol (2004) 2.52
On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim. Health Aff (Millwood) (2013) 2.26
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2010) 2.16
An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. Health Aff (Millwood) (2012) 2.16
The European Working Time Directive: an uncontrolled experiment in medical care and education. JAMA (2013) 2.10
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ (2013) 2.04
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Consequences of health trends and medical innovation for the future elderly. Health Aff (Millwood) (2005) 1.95
A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer (2012) 1.85
Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol (2010) 1.84
Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med (2012) 1.83
Out-of-pocket medication costs and use of medications and health care services among children with asthma. JAMA (2012) 1.83
Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care (2007) 1.80
Hospital spending and inpatient mortality: evidence from California: an observational study. Ann Intern Med (2011) 1.79
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Estimation of encounter-level hospitalization costs: accuracy of a multivariate prediction model. Med Care Res Rev (2003) 1.74
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Drug licenses: a new model for pharmaceutical pricing. Health Aff (Millwood) (2008) 1.39
Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood) (2012) 1.38
Do variations in provider discussions explain socioeconomic disparities in postmastectomy breast reconstruction? J Am Coll Surg (2008) 1.31
Measuring the improving quality of outpatient care in medical oncology practices in the United States. J Clin Oncol (2013) 1.30
Surviving colorectal cancer : patient-reported symptoms 4 years after diagnosis. Cancer (2007) 1.21
Hospital value-based purchasing. J Hosp Med (2013) 1.21
Symptom management after breast cancer treatment: is it influenced by patient characteristics? Breast Cancer Res Treat (2007) 1.16
Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care (2010) 1.15
Developing a reliable, valid, and feasible plan for quality-of-care measurement for cancer: how should we measure? Med Care (2002) 1.14
An economic evaluation of the war on cancer. J Health Econ (2010) 1.13
The promise of health care cost containment. Health Aff (Millwood) (2007) 1.13
The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood) (2008) 1.13
Symptoms after breast cancer treatment: are they influenced by patient characteristics? Breast Cancer Res Treat (2007) 1.12
Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat (2012) 1.09
Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies. Ann Intern Med (2015) 1.02
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) (2012) 1.01
Medicare part D after 2 years. Am J Manag Care (2009) 0.99
Cancer Quality-ASSIST supportive oncology quality indicator set: feasibility, reliability, and validity testing. Cancer (2010) 0.98
The impact of comparative effectiveness research on health and health care spending. J Health Econ (2011) 0.98
Financial incentives for quality in breast cancer care. Am J Manag Care (2008) 0.97
Impact of oral nutritional supplementation on hospital outcomes. Am J Manag Care (2013) 0.97
Trends in the earnings of health care professionals in the United States, 1987-2010. JAMA (2012) 0.97
Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer (2012) 0.95
Patient preference and contraindications in measuring quality of care: what do administrative data miss? J Clin Oncol (2013) 0.95
Quality of end-of-life care for patients with advanced cancer in an academic medical center. J Palliat Med (2011) 0.94
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas (2013) 0.93
Spending and mortality in US acute care hospitals. Am J Manag Care (2013) 0.93
Quality of prostate cancer care among rural men in the Veterans Health Administration. Cancer (2013) 0.93
The pragmatist's guide to comparative effectiveness research. J Econ Perspect (2011) 0.92
Predicting new diagnoses of HIV infection using internet search engine data. Clin Infect Dis (2013) 0.91
Documentation and discussion of preferences for care among patients with advanced cancer. J Oncol Pract (2011) 0.90
Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ (2009) 0.90
Guidance for structuring team-based incentives in healthcare. Am J Manag Care (2013) 0.89
Defense costs of medical malpractice claims. N Engl J Med (2012) 0.89
Reducing Diagnostic Errors--Why Now? N Engl J Med (2015) 0.89
Disability forecasts and future Medicare costs. Front Health Policy Res (2004) 0.88
The economics of intense exercise. J Health Econ (2010) 0.87
Wrestling with the high price of cancer care: should we control costs by individuals' ability to pay or society's willingness to pay? J Clin Oncol (2010) 0.87
Annual expenditures for nursing home care: private and public payer price growth, 1977 to 2004. Med Care (2009) 0.86
Physician and Practice Characteristics Influencing Tumor Board Attendance: Results From the Provider Survey of the Los Angeles Women's Health Study. J Oncol Pract (2011) 0.86
Prevalence, predictors, and patient outcomes associated with physician co-management: findings from the Los Angeles Women's Health Study. Health Serv Res (2011) 0.85
Reconsidering the Veterans Health Administration: a model and a moment for publicly funded health care delivery. Ann Intern Med (2011) 0.84
Improving colorectal cancer screening rates in a managed care health plan: recruitment of provider organizations for a randomized effectiveness trial. Cancer Epidemiol Biomarkers Prev (2003) 0.83
Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manag Care (2010) 0.83
Preoperative breast MRI in early-stage breast cancer. Breast Cancer Res Treat (2012) 0.83
The structural landscape of the health care system for breast cancer care: results from the Los Angeles Women's Health Study. Breast J (2008) 0.83
The value of medical and pharmaceutical interventions for reducing obesity. J Health Econ (2012) 0.82
Value of survival gains in chronic myeloid leukemia. Am J Manag Care (2012) 0.82
The impact of insulin type on severe hypoglycaemia events requiring inpatient and emergency department care in patients with type 2 diabetes. Diabetes Res Clin Pract (2013) 0.82
Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest (2015) 0.81
Postinterview communication between military residency applicants and training programs. Mil Med (2012) 0.81
Use of interpreters by physicians treating limited English proficient women with breast cancer: results from the provider survey of the Los Angeles Women's Health Study. Health Serv Res (2009) 0.81
Is the Food and Drug Administration safe and effective? J Econ Perspect (2008) 0.81
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. BMC Cancer (2011) 0.80
Polymerase translocation with respect to single-stranded nucleic acid: looping or wrapping of primer around a poly(A) polymerase. Structure (2009) 0.80
Value of expanding HCV screening and treatment policies in the United States. Am J Manag Care (2016) 0.80
Can an acute pain service be cost-effective? Anesth Analg (2010) 0.79
Structure-based design of Aurora A & B inhibitors. J Comput Aided Mol Des (2008) 0.79
When hope hinders science and patient-centered care. J Clin Oncol (2012) 0.79
Facility characteristics and quality of lung cancer care in an integrated health care system. J Thorac Oncol (2014) 0.78
Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Am J Manag Care (2014) 0.78
The wider public health value of HCV treatment accrued by liver transplant recipients. Am J Manag Care (2016) 0.77
The cost-quality trade-off: need for data quality standards for studies that impact clinical practice and health policy. J Clin Oncol (2005) 0.77
Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol (2004) 0.77
Falsification end points for observational studies--reply. JAMA (2013) 0.77
Medication adherence and measures of health plan quality. Am J Manag Care (2015) 0.77
Costs and spillover effects of private insurers' coverage of hepatitis C treatment. Am J Manag Care (2016) 0.76
Balancing disease eradication with the emergence of multidrug-resistant HIV in test-and-treat policies. Clin Infect Dis (2013) 0.76